Detail akcie Sera Prognstcs Rg-A online

Business Summary: Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Sera Prognostics Inc revenues increased 34% to $71K. Net loss decreased 1% to $24M. Revenues reflect Medical diagnostic products segment increase from $29K to $71K. Basic Earnings per Share excluding Extraordinary Items increased from -$0.74 to -$0.52.